Basic Research
Clinical significance of exosomal miR-1231 in pancreatic cancer
Chen Shilin, Ma Min, Yan Lei, Xiong Shuhan, Liu Zhuo, Li Sha, Liu Teng, Shang Song, Zhang Yuying, Zeng Hui, Xie Hailong, Zuo Chaohui
Published 2019-01-23
Cite as Chin J Oncol, 2019, 41(1): 46-49. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008
Abstract
ObjectiveTo investigate the expression and clinical significance of exosomal miR-1231 in plasma of pancreatic cancer (PC) patients and pancreatic cancer cells.
MethodsA total of 16 patients who were diagnosed with pancreatic cancer in Hunan Cancer Hospital were collected from April 2016 to August 2017. Meanwhile, 16 healthy volunteers were recruited as the healthy control group at the same period. The plasma exosomes were extracted, and the levels of miR-1231 were detected by qRT-PCR in PC and healthy control groups. Moreover, the clinicopathological significance of exosomal miR-1231 expression was analyzed. Furthermore, the expression of exosomal miR-1231 was detected in several pancreatic cancer cells (MIA PaCa-2, PANC-1, SW1990, AsPC-1 and BxPc-3) and two normal pancreatic epithelial cells (HPDE and human primary pancreatic epithelial cell).
ResultsqRT-PCR results showed that the expression level of miR-1231 in plasma exosomes of pancreatic cancer patients (1.06±0.46) was significantly lower than that in healthy controls (2.30±0.99; P<0.05). The levels of exosomal miR-1231 in patients with stage Ⅰ-Ⅱ (1.515±0.531), no distant metastasis (1.236±0.461) and no lymph node metastasis (1.337±0.522) were significantly higher than those with stage Ⅲ-Ⅳ (0.848±0.224), distant metastasis (0.757±0.278) and lymph node metastasis (0.838±0.261), respectively (P<0.05 for all). In addition, there were no correlation between exosomal miR-1231 expression and age, sex, smoking history, CA19-9 levels and tumor sites (P>0.05). Furthermore, the expression level of exosomal miR-1231 in pancreatic cancer cell lines (0.142±0.135) was significantly lower than that in normal epithelial cells (1.127±0.179;P<0.05).
ConclusionsThe downregulation of exosomal miR-1231 in plasma of pancreatic cancer patients and pancreatic cancer cells suggests that it is related to the initiation and development of PC. It may be a new diagnostic and prognostic marker for PC.
Key words:
Pancreatic neoplasms; Exosomes; MicroRNA-1231; Clinicopathological features
Contributor Information
Chen Shilin
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Ma Min
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Yan Lei
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Xiong Shuhan
School of Public Health, Jilin University, Changchun 130021, China
Liu Zhuo
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Li Sha
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Liu Teng
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Shang Song
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Zhang Yuying
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Zeng Hui
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
Xie Hailong
Cancer Research Institute, University of South China, Hengyang 421001, China
Zuo Chaohui
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School Medicine, Central South University, Changsha 410013, China
